Contralateral_primary_tumors_in_breast_cancer_patients_in_a_randomized_trial_of_adjuvant_tamoxifen_therapy__Prophylactic_treatment_with_the_anti-estrogen_tamoxifen_may_reduce_the_risk_of_breast_cancer_because_estrogens_are_thought_to_act_as_promoters_in_the_pathogenesis_of_the_disease._This_article_presents_results_on_the_incidence_of_contralateral_new_primary_tumors_among_1846_postmenopausal_breast_cancer_patients_included_in_a_randomized_trial_of_adjuvant_tamoxifen_therapy_for_2_or_5_years_after_surgery_versus_no_adjuvant_endocrine_therapy._The_median_follow-up_was_7_years_(range,_3-13_years)._There_was_a_significant_reduction_of_contralateral_breast_cancer_in_the_931_patients_in_the_tamoxifen_group_versus_that_in_the_915_control_patients_(29_versus_47_cases,_respectively;_P_=_.03)._The_cumulative_incidence_at_10_years_in_the_tamoxifen_group_and_the_control_group_was_5%_and_8%,_respectively._Analysis_of_the_relative_hazard_of_contralateral_tumor_over_time_showed_that_the_benefit_with_tamoxifen_therapy_was_greatest_during_the_first_1-2_years,_but_there_was_a_continued_risk_reduction_during_the_entire_follow-up_period,_i.e.,_more_than_10_years_after_cessation_of_treatment._There_was_no_significant_difference_in_the_number_of_contralateral_cancers_in_the_patients_randomly_assigned_to_2_or_5_years_of_treatment,_but_the_95%_confidence_interval_of_the_relative_hazard_was_wide._The_proportion_of_estrogen_receptor-negative_contralateral_breast_cancers_was_higher_in_the_tamoxifen_group_than_in_the_control_group._There_was_no_difference,_however,_between_the_two_groups_in_recurrence-free_survival_time_from_the_diagnosis_of_the_contralateral_cancer.